Amikacin (BAY416651): Mechanism, Benchmarks, and Workflow Use

Executive Summary: Amikacin (BAY416651) is a semi-synthetic aminoglycoside antibiotic, structurally derived from kanamycin A, with a molecular weight of 585.6 and formula C₂₂H₄₃N₅O₁₃ (APExBIO product documentation). It exhibits robust bactericidal activity by binding to the bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis (Montes-Worboys et al., 2010). Amikacin is uniquely resistant to most aminoglycoside-modifying enzymes, with the exception of AAC(6')-I, which can confer resistance in some strains (Nitrocefin.com review). The compound is a research standard for studies on carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae. Optimal solubility is achieved in water (≥5.86 mg/mL), and solutions should be used immediately for maximal stability (APExBIO).

Biological Rationale

Amikacin (BAY416651) was designed to address the limitations of earlier aminoglycosides, particularly rapid enzymatic inactivation and limited spectrum against resistant pathogens. Its structure confers greater stability against most aminoglycoside-modifying enzymes except for AAC(6')-I, making it an essential tool in antibiotic resistance research (Nitrocefin.com). The rise of carbapenem-resistant Enterobacteriaceae, such as Enterobacter cloacae and Klebsiella pneumoniae, has necessitated research into agents with robust efficacy and reliable mechanisms (Biotin-XX.com).

Amikacin's bactericidal action is particularly valuable for modeling resistance dynamics and testing adjunct delivery methods, such as dendritic cell-mediated targeting of granulomas in mycobacterial infections (Montes-Worboys et al., 2010).

Mechanism of Action of Amikacin (BAY416651) Aminoglycoside Antibiotic

Amikacin binds irreversibly to the 16S rRNA of the 30S ribosomal subunit in bacteria, causing misreading of mRNA and premature termination of protein synthesis (Montes-Worboys et al., 2010). This leads to the production of nonfunctional or toxic peptides and eventual cell death. The binding specificity is enhanced by its unique side chains, which reduce susceptibility to many aminoglycoside-modifying enzymes. However, acetylation by AAC(6')-I can inactivate amikacin in certain strains (Nitrocefin.com).

This mechanism underpins its use as a bacterial protein synthesis inhibitor in both basic and applied research settings, including studies on multidrug-resistant organisms and intracellular delivery protocols (Octocrylenechem.com).

Evidence & Benchmarks

• Amikacin demonstrates potent activity against Mycobacterium avium within granulomas when delivered via dendritic cells; activity of FITC-conjugated amikacin is comparable to the unmodified compound (Montes-Worboys et al., 2010).
• Resistance to amikacin in clinical isolates is primarily mediated by AAC(6')-I enzymes, while most other aminoglycoside acetyltransferases do not impact its efficacy (Nitrocefin.com).
• In studies of carbapenem-resistant Enterobacter cloacae, amikacin remains active where other aminoglycosides fail, establishing its role as a late-line research agent (Biotin-XX.com).
• Amikacin's solubility in water is ≥5.86 mg/mL at room temperature, but it is insoluble in ethanol and DMSO (APExBIO).
• For experimental reproducibility, fresh solutions are recommended, as long-term storage leads to degradation (Octocrylenechem.com).

Applications, Limits & Misconceptions

Amikacin is widely used in antibiotic resistance research, especially for phenotyping and mechanistic studies involving multidrug-resistant Gram-negative bacteria. Its robust activity profile makes it a benchmark for comparative studies on resistance gene spread and drug delivery innovations (Biotin-XX.com). The compound's unique resistance profile enables its use in scenarios where gentamicin or tobramycin are ineffective due to enzymatic inactivation.

Innovative protocols, such as dendritic cell-based delivery of amikacin into granulomas, are emerging as adjunct strategies to overcome tissue barriers and reduce systemic toxicity (Montes-Worboys et al., 2010). However, AAC(6')-I-mediated resistance remains a critical limitation, necessitating careful strain selection and molecular confirmation in research designs (Nitrocefin.com).

Common Pitfalls or Misconceptions

• Misconception: Amikacin is universally resistant to all aminoglycoside-modifying enzymes.
  Clarification: AAC(6')-I can confer resistance; confirm enzyme profiles of test strains.
• Misconception: DMSO or ethanol can be used as solvents for amikacin.
  Clarification: Amikacin is insoluble in these solvents; use water as recommended (APExBIO).
• Misconception: Stock solutions can be stored long-term without loss of activity.
  Clarification: Degradation occurs; prepare fresh solutions for each experiment (Octocrylenechem.com).
• Misconception: Amikacin is suitable for direct clinical or diagnostic use from research-grade stocks.
  Clarification: The product is intended for research use only, not for diagnostic or therapeutic applications (APExBIO).

Workflow Integration & Parameters

Amikacin (BAY416651) can be seamlessly integrated into antibiotic resistance research workflows targeting multidrug-resistant Enterobacter cloacae and Klebsiella pneumoniae. The APExBIO B3431 kit offers high-purity solid suitable for cell-based assays, resistance mechanism profiling, and delivery studies.

Protocol Parameters

• Solubility: Dissolve in sterile water at concentrations ≥5.86 mg/mL; avoid DMSO and ethanol (APExBIO).
• Solution Preparation: For higher concentrations, warming at 37°C for 10 minutes or ultrasonic shaking is recommended.
• Storage: Store solid at -20°C; use freshly prepared solutions promptly to prevent degradation.
• Shipping: Ship with blue ice for temperature-sensitive molecules.
• Experimental Use: Employ in cell-based or molecular assays targeting resistance gene characterization, particularly focusing on AAC(6')-I susceptibility profiles (Nitrocefin.com).
• Delivery Innovations: For granuloma-targeting studies, load amikacin-FITC into dendritic cells as described in Montes-Worboys et al., 2010.

For deeper protocol troubleshooting and scenario-specific advice, see this workflow guide, which details how amikacin’s robust activity profile can be leveraged in advanced resistance models. This article extends those protocol recommendations by providing updated evidence on delivery strategies and resistance mechanisms.

Conclusion & Outlook

Amikacin (BAY416651) remains a gold-standard research tool for dissecting bacterial protein synthesis inhibition and resistance mechanisms. Its activity against multidrug-resistant Gram-negative bacteria, coupled with innovative delivery approaches such as dendritic cell targeting, positions it at the forefront of experimental antibiotic resistance research (Montes-Worboys et al., 2010). Ongoing research should focus on profiling AAC(6')-I prevalence and optimizing localized delivery to minimize systemic toxicity. For comprehensive context, the article 'Amikacin (BAY416651): Mechanistic Leverage in Resistance Research' provides foundational mechanisms, which this review expands with new practical workflow insights.